A brief history of cannabinoid and endocannabinoid pharmacology as inspired by the work of British scientists

被引:83
作者
Di Marzo, V [1 ]
机构
[1] CNR, Endocannabinoid Res Grp, Inst Biomol Chem, I-80078 Pozzuoli, NA, Italy
关键词
D O I
10.1016/j.tips.2006.01.010
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
British scientists have played a leading role in the long history of cannabinoid and endocannabinoid research. Such research has progressed from the first crucial evaluation of the medicinal properties of Cannabis sativa in the Western world to pioneering studies of the chemical constituents of this plant, the development of in vitro biological assays to study cannabinoids, the identification of the mechanism of action of cannabinoids, the discovery of endocannabinoids and the assessment of their therapeutic implications. Stemming from the many innovative ideas and achievements of these researchers, I provide a personal view of where these studies have led us thus far and where they are likely to take us in the future.
引用
收藏
页码:134 / 140
页数:7
相关论文
共 72 条
[1]   Structure of cannabinol. III. Synthesis of cannabinol, 1-hydroxy-3-n-amyl-6,6,9-trimethyl-6-dibenzopyran [J].
Adams, R ;
Baker, BR ;
Wearn, RB .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1940, 62 :2204-2207
[2]   Anandamide regulates neuropeptide release from capsaicin-sensitive primary sensory neurons by activating both the cannabinoid 1 receptor and the vanilloid receptor 1 in vitro [J].
Ahluwalia, J ;
Urban, L ;
Bevan, S ;
Nagy, I .
EUROPEAN JOURNAL OF NEUROSCIENCE, 2003, 17 (12) :2611-2618
[3]   Anandamide is able to inhibit trigeminal neurons using an in vivo model of trigeminovascular-mediated nociception [J].
Akerman, S ;
Kaube, H ;
Goadsby, PJ .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 309 (01) :56-63
[4]   Cannabinoids control spasticity and tremor in a multiple sclerosis model [J].
Baker, D ;
Pryce, G ;
Croxford, JL ;
Brown, P ;
Pertwee, RG ;
Huffman, JW ;
Layward, L .
NATURE, 2000, 404 (6773) :84-87
[5]   Evidence for novel cannabinoid receptors [J].
Begg, M ;
Pacher, P ;
Bátkai, S ;
Osei-Hyiaman, D ;
Offertáler, L ;
Mo, FM ;
Liu, H ;
Kunos, G .
PHARMACOLOGY & THERAPEUTICS, 2005, 106 (02) :133-145
[6]   Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain [J].
Bisogno, T ;
Howell, F ;
Williams, G ;
Minassi, A ;
Cascio, MG ;
Ligresti, A ;
Matias, I ;
Schiano-Moriello, A ;
Paul, P ;
Williams, EJ ;
Gangadharan, U ;
Hobbs, C ;
Di Marzo, V ;
Doherty, P .
JOURNAL OF CELL BIOLOGY, 2003, 163 (03) :463-468
[7]   An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis [J].
Brady, CM ;
DasGupta, R ;
Dalton, C ;
Wiseman, OJ ;
Berkley, KJ ;
Fowler, CJ .
MULTIPLE SCLEROSIS JOURNAL, 2004, 10 (04) :425-433
[8]   Rimonabant: The first therapeutically relevant cannabinoid antagonist [J].
Carai, MAM ;
Colombo, G ;
Gessa, GL .
LIFE SCIENCES, 2005, 77 (19) :2339-2350
[9]   The capsaicin receptor: a heat-activated ion channel in the pain pathway [J].
Caterina, MJ ;
Schumacher, MA ;
Tominaga, M ;
Rosen, TA ;
Levine, JD ;
Julius, D .
NATURE, 1997, 389 (6653) :816-824
[10]   The cannabinoid CB1 receptor antagonist, SR141716A, selectively facilitates nociceptive responses of dorsal horn neurones in the rat [J].
Chapman, V .
BRITISH JOURNAL OF PHARMACOLOGY, 1999, 127 (08) :1765-1767